IBB News and Press, iShares Biotechnology ETF From 07/11/22

Biogen is beginning to have a trend change. Biogen is at the bottom of a trading range that goes back 10 years. Now may be a good time to initiate a position with earnings coming soon. As I look at price charts at the end of the week for potential buys or shorts I notice...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips My son became an investor this year, taking a job that pays more than his single, frugal lifestyle consumes. He asked me what stocks he might buy with just $100. It was a difficult question. Finding the best stocks for $...

DexCom has a leading position in a huge and growing market of continuous glucose monitoring. Medical technology is a growing space, with powerful demographic forces leading to outsized long-term growth. The stock has pulled back to an entry point that has it a strong buy for a 5+ ...

Ublituximab used to be TGTX's second asset and a very large potential icing on the cake for the company. After umbralisib went down, ubli has become its lifeline. While data is consistently good, one wonders what the FDA asked for with the new data that led to a delay. F...

Why the economy, practically speaking, may already be in recession. Why defensive sectors may be worth a closer look in the current environment. Market sentiment might be bearish, but that doesn't mean there aren't opportunities. Aggressive moves by central banks...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips “Time is on my side, yes it is.” If you’re of a certain age the message sings to you. But the stock market doesn’t heed those words, and truly strong opportunities to boost long-term returns are ...

Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee (IDMC) to proceed with the planned trial. With the help of Biorasi, Citius could reach full patient enrolment by the end of 2022, as e...

Microsatellite stable colorectal cancer patients who had a molecular response who took GRANITE combination exceeded mOS of 18 months and mOS has not yet been reached. The global market opportunity for colorectal cancer is expected to reach $18.5 billion by 2023. Results from the p...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks have been brought low over the past 18 months. Both the iShares Biotechnology ETF (NASDAQ: IBB ) and S&P Biotech ETF (NYSEARCA: XBI ), Wall Street’s two most popular funds that track th...

Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the European Union. Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the United Kingdom. PDUFA date for potential FDA approval of Yselty for...